Meanwhile, the Company is also an authorized agent for sales of the new high-tech medical apparatus and instruments as follows:

The company has pioneered several first-in-China products, including:

• The first in vitro diagnostic kit for detecting three types of autoantibodies related to inflammatory bowel disease (IBD),
• The first optical pulse device for dry eye treatment,
• A binocular dry eye diagnostic instrument.

In addition, Rui Hao Biotech has developed a range of innovative products such as:

• A rapid diagnostic kit for myocardial infarction,
• An immunoglobulin G4 (IgG4) antibody test,
• A vasculitis antibody diagnostic kit,
• A corneal topographer,
• An intelligent amblyopia treatment headset for children,
• An aerosol-based automatic air purifier,
• And a pulse-based disinfection robot.

In its next phase of development, the company will focus on integrating optoelectronic technologies with immunodiagnostics. Using big data models, image recognition, and machine learning, RH aims to develop intelligent ophthalmic devices that integrate screening, diagnosis, and treatment functionalities.